Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.89 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 19.89
Bid (Size) 19.45 (100)
Ask (Size) 20.72 (100)
Prev. Close 19.89
Today's Range 19.89 - 19.89
52wk Range 19.59 - 30.96
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-24.3%
-24.3%
1 Month
-31.2%
-31.2%
3 Month
-23.4%
-23.4%
6 Month
-10.4%
-10.4%
1 Year
-6.4%
-6.4%

More News

Read More
News headline image
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial ↗
Via MarketBeat
News headline image
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup ↗
Via Chartmill
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data ↗
Via MarketBeat
News headline image
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
Via Chartmill
Topics Earnings
News headline image
ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Acadia Pharmaceuticals Stock Is Soaring Today ↗
Via The Motley Fool
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
Via MarketBeat
News headline image
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
Via MarketBeat
News headline image
Acadia (ACAD) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
From Acadia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 19.89
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 10/01/26 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.23B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.